Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dabigatran versus warfarin for pediatric thromboembolism
IRCT20180711040431N1Phase 3Completed
- Sponsor
- Arak University of Medical Sciences
- Start
- Jul 2018
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label trial of dabigatran, warfarin and enoxaparin in thromboembolism (2 arms), sponsored by Arak University of Medical Sciences. Primary endpoints: Incidence of bleeding, Recurrent thromboembolism and 2 more. Started Jul 2018; status: completed.
02
Drugs
dabigatranwarfarinenoxaparin
03
Conditions
thromboembolism
Beyond the preview
Go deeper on IRCT20180711040431N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20180711040431N1.